Blue Owl Capital Holdings LP Makes New $1.52 Million Investment in KalVista Pharmaceuticals, Inc. $KALV

Blue Owl Capital Holdings LP acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 125,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,522,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its position in shares of KalVista Pharmaceuticals by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after purchasing an additional 818 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares in the last quarter. Rhumbline Advisers increased its holdings in KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in KalVista Pharmaceuticals by 26.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock valued at $110,000 after buying an additional 2,061 shares during the period. Finally, Profund Advisors LLC boosted its holdings in shares of KalVista Pharmaceuticals by 25.9% during the 3rd quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company’s stock worth $154,000 after buying an additional 2,593 shares in the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In related news, CFO Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the sale, the chief financial officer owned 13,762 shares of the company’s stock, valued at approximately $214,274.34. This trade represents a 11.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 5,354 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $83,361.78. Following the sale, the insider owned 138,983 shares of the company’s stock, valued at $2,163,965.31. This trade represents a 3.71% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 33,979 shares of company stock worth $535,091. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

KALV has been the subject of several recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Citizens Jmp cut their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Tuesday, November 11th. Needham & Company LLC raised their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.40.

KalVista Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ:KALV opened at $16.23 on Friday. The business’s 50 day simple moving average is $15.57 and its two-hundred day simple moving average is $14.11. The firm has a market cap of $820.43 million, a P/E ratio of -4.11 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.23 and a 52-week high of $19.00.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.